Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes

Pelluri, Ranakishor; Kongara, S; Nagasubramanian, V R; Mahadevan, S; Chimakurthy, J

doi:10.1007/s40618-023-02003-9

Cited by 6 publications

(3 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observations of the present study imply that teneligliptin, at a once daily dose of 10 mg and 20mg, is considered to be safe and effective in weight loss in non-diabetic individuals without causing hypoglycemia. However, though it is not a serious AE, URTI following teneligliptin therapy in 23% of study population was also reported by a study done in chinese population [41], as well as a recent metaanalysis also revealed that the adverse outcomes are not signi cant in patients treated with teneligliptin alone in diabetics [42]. Overall, present study identi ed that teneligliptin was safe and effective in weight reduction of non-diabetic obese individuals.…”

Section: Discussionsupporting

confidence: 75%

Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals

Pelluri,

Kongara,

Nagasubramanian

et al. 2024

Metabolic Syndrome and Related Disorders

View full text Add to dashboard Cite

Background and aims: Teneligliptin is an oral anti-diabetic agent, it can persevere GLP-1 by inhibiting DPP-4 enzyme. Also had rare incidence of hypoglycemia. Hence, the present study was aimed to test the effect of teneligliptin 20 mg twice daily along with low carbohydrate diet and physical exercise on change of body weight, insulin resistance in non-diabetic obese subjects.Methods: It is a prospective, randomized, placebo controlled, parallel group study carried out at outpatient department of an endocrinology hospital over the period of 48 weeks. Teneligliptin 20 mg twice daily 30 min before food (Low carbohydrate diet) with regular physical exercise and control group was kept with only LCD diet and regular physical exercise. The present Study was registered in clinical trial registry of India [CTRI/2020/02/023329].Results: A total of 150 non diabetic obese subjects were randomized into test (n=75) and control group (n=75). At the end of the 48th weeks signi cant improvement of GLP-1, SNAQ score, HOMA-IR, Triglycerides, and body weight. The mean difference and 95% CI of GLP-1 (pg/mL) was 76.42 (44.42, 148.41) (p 0.37); SNAQ score, -1.64 (-2.48, -0.81) (p 0.000); HOMA-IR, -0.9 (-0.59, -0.38) (p 0.000); Triglycerides (mg/dL) -29.37 (-44.46, -14.07) (p 0.000); reduction of body weight (kg) -3.09 (-6.11, -0.07) (p 0.043).Conclusion: Findings of this study reveals that teneligliptin treated group showed signi cant improvement of GLP-1 levels, reduced insulin resistance, body weight, triglycerides, appetite, and metabolic syndrome. Teneligliptin is well tolerated, except upper respiratory tract infections.

show abstract

Section: Discussionsupporting

confidence: 75%

Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals

Pelluri,

Kongara,

Nagasubramanian

et al. 2024

Metabolic Syndrome and Related Disorders

View full text Add to dashboard Cite

show abstract

“…In a systematic review and meta-analysis, no significant risk of any hypoglycemia with Teneligliptin as compared to placebo (OR 0.84; 95% CI 0.44-1.60; I 2 = 0%; P = 0.60) was found, but the risk was 1.84 times higher when combined with other hypoglycemic agents [25]. A post-marketing surveillance of more than 10,000 patients on Teneligliptin reported the occurrence of adverse effects in 3.85% of patients.…”

Section: Discussionmentioning

confidence: 98%

An Observational Retrospective Real-World Study to Evaluate the Effect of Teneligliptin on Parameters of Renal Function, Glycemic Control, and Safety in Indian T2DM Patients with Chronic Kidney Disease (TOP RENAL)

2024

Curr Trends Intern Med

View full text Add to dashboard Cite

Background: Teneligliptin has shown better efficacy, tolerability and reduced associated complications in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). The aim of this study was to evaluate the effect of Teneligliptin on renal function and glycemic control in Indian T2DM patients with CKD in a real-world setting.Methodology: This was a retrospective, observational study that included 377 patients from 4 study sites across India. Details from prescriptions and laboratory investigations of individual patient were recorded. Primary and secondary outcomes measured were changes in the renal parameters, [eGFR, serum creatinine, and blood urea nitrogen] and glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), and body weight at 3 months and 6 months (±2week) as compared to baseline.

show abstract

“…It exerts its antidiabetic function by increasing the blood concentration of GLP-1 [ 13 , 14 ]. Teneligliptin was first developed by Mitsubishi Tanabe Pharma and approved for treating T2DM in Japan in 2012, with its promising antidiabetic function proven in several clinical trials [ 15 , 16 ]. DPP-4 inhibitors could be classified into peptidomimetic (i.e., sitagliptin, vildagliptin, saxagliptin, and anagliptin) and non-peptidomimetic (i.e., alogliptin and linagliptin) subtypes.…”

Section: Introductionmentioning

confidence: 99%

Teneligliptin alleviates diabetes-related cognitive impairment by inhibiting the endoplasmic reticulum (ER) stress and NLRP3 inflammasome in mice

Wang,

Zhang

2023

Aging

View full text Add to dashboard Cite

Diabetes mellitus (DM) significantly influences the normal health of patients with its severe complications, including diabetes-related cognitive impairment (CI). Recently, neuroinflammation and oxidative stress (OS) have been reported to participate in the pathogenesis of diabetes-related CI. Teneligliptin, an inhibitor of DDP-IV, was developed for treating DM and is claimed with promising effects against inflammation. Herein, in the current study, we examined the potential therapeutic function of Teneligliptin against diabetes-related CI. Db/m or diabetic mice were orally administered with teneligliptin (60 mg/kg/day) for 10 weeks. Elevated levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C), increased escape latency, declined time in the platform quadrant and decreased number of platform crossings in the Morris water maze test, reduced freezing index in the fear conditioning test, and lessened time spent in the novel arm and percentage of alterations in the Y-maze test were observed in diabetic mice, all of which were sharply improved by teneligliptin. Furthermore, increased levels of inflammatory cytokines and activated OS state were observed in the hippocampus of diabetic mice, which were markedly repressed by Teneligliptin. Lastly, the activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) signaling and the endoplasmic reticulum (ER) stress pathway in the hippocampus of diabetic mice were notably inhibited by teneligliptin. Collectively, teneligliptin mitigated diabetes-related CI by repressing the ER stress and NLRP3 inflammasome in diabetic mice.

show abstract

Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes

Cited by 6 publications

References 69 publications

Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals

Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals

An Observational Retrospective Real-World Study to Evaluate the Effect of Teneligliptin on Parameters of Renal Function, Glycemic Control, and Safety in Indian T2DM Patients with Chronic Kidney Disease (TOP RENAL)

Teneligliptin alleviates diabetes-related cognitive impairment by inhibiting the endoplasmic reticulum (ER) stress and NLRP3 inflammasome in mice

Contact Info

Product

Resources

About